What Is the Future of Factor XI Inhibitors? | Circulation
2022年12月19日 · FXI inhibitors include (1) fesomersen, a second-generation antisense oligonucleotide that reduces the hepatic synthesis of FXI; (2) monoclonal antibodies that inhibit FXI activation, FXIa activity, or both (eg, osocimab and abelacimab); and (3) asundexian and milvexian, small molecule FXIa inhibitors.
Abelacimab for Prevention of Venous Thromboembolism
2021年7月19日 · Factor XI inhibition with a single intravenous dose of abelacimab after total knee arthroplasty was effective for the prevention of venous thromboembolism and was associated with a low risk of...
Pharmacology and Clinical Development of Factor XI Inhibitors
2023年3月13日 · Inhibition of factor XI (FXI) has emerged as a strategy with the potential to uncouple the pharmacological effect and the adverse events of anticoagulant therapy.
Factor XI Inhibitors for Prevention and Treatment of Venous ...
Direct oral anticoagulants (i.e., factor IIa- and factor Xa-inhibitors) now dominate clinical practice because of their favorable pharmacological profile and ease of use, particularly in venous thromboembolism (VTE) treatment and stroke prevention in atrial fibrillation.
New Therapeutic Targets for the Prevention and Treatment of …
2023年8月31日 · The current focus is on factor XI inhibitors, which have the potential to uncouple thrombosis and hemostasis, thereby providing safer anticoagulation. Phase 3 trials with factor XI inhibitors for venous thromboembolism treatment are underway.
Factor XI inhibitors: The ongoing search for anticoagulation …
In all these conditions, and in attempt of reducing bleeding risk of DOACs, research has turned to factor XI/XIa inhibitors. The coagulation cascade (hemostasis) is mainly divided into 3 major pathways: intrinsic (the contact pathway), extrinsic (the tissue factor pathway) and common.
The new in anticoagulation: factor XI inhibitors - PMC
2023年4月23日 · However, epidemiological and experimental evidence suggests that inhibiting the contact pathway—the first phase of the intrinsic coagulation pathway—and especially factor XI (FXI) achieves the objective of preventing thrombosis with minimal interference on the haemostatic process.
Factor XI Inhibitors: A New Horizon in Anticoagulation Therapy
2024年2月2日 · This comprehensive review delves into several key aspects regarding this new target: (i) the role of factor XI in the coagulation cascade; (ii) the genetic evidence and pathophysiologic rationale supporting factor XI inhibition as a therapeutic target; (iii) an exploration of the various types of factor XI/XIa inhibitors currently under ...
What Now for Factor XI Inhibitors in AF? - Medscape
2024年12月11日 · Factor XI inhibitors are also being tested in phase 3 studies of patients with noncardioembolic stroke including the ongoing OCEANIC-Stroke study. “The science is there,” Angiolillo said ...
A new strategy for anticoagulation: The factor XI inhibitors
2023年7月2日 · Factor XI inhibitors are in more advanced phases of clinical development and clinical data have recently been made available. Some studies showed that inhibiting contact activation of factor XI can reduce thrombosis induced by artificial surfaces without the bleeding risks of traditional anticoagulants.
- 某些结果已被删除